SPRYCEL (Dasatinib) Tablets

dasatinib Tablet
for Oral Use Initial U.S. Approval: 2006

SPRYCEL is a kinase inhibitor indicated for the treatment of • newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.

Facts about Dasatinib Tablets

Approval Date: 2006
Proprietary Name: On Request
Active Ingredient(s): Dasatinib Tablets
Dosage Forms And Strengths: Tablets: 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg.
Company: Bristol-Myers Squibb
Current indications: chronic Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML)
Medicine Approved By: – European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “Dasatinib Tablets” based on the information you provide.

Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India. With over two decades of industry experience, IPN offers extensive coverage across India, including prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.